Sangamo diabetes drug shows positive results

[admin]

Sangamo BioSciences Inc. said Monday its drug for diabetes-related nerve damage helped relieve instances of the problem involving “blocked” nerves in people’s lower limbs.

The results, based on interim data from a mid-stage test of Sangamo’s drug SB-509, showed potential for the treatment of patients the company said had “until now ... been considered impossible to treat.”

Another test of Sangamo’s (NASDAQ: SGMO) drug using a separate measure of its ability to help diabetics regain nerve sensitivity also showed positive results, the Richmond company said.

Sangamo president and CEO Edward Lanphier said he was “very encouraged by the safety of SB-509” in tests.